MD Anderson and Biocept Scientists to Present Poster at ASCO on Disseminated Tumor Cells (DTCs) in Bone Marrow and Circulating Tumor Cells (CTCs) in Blood in Early Stage Breas...
SAN DIEGO, June 2, 2011 /PRNewswire/ -- Data to be presented in a poster at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, Illinois June 3-7 by researchers from The University of Texas MD Anderson Cancer Center and Biocept, Inc. show that a laboratory test developed by Biocept, Inc. for the evaluation of HER2 status of Circulating Tumor Cells (CTCs) and Disseminated Tumor Cells (DTCs) can provide potentially valuable information to physicians treating breast cancer patients, different from that obtained through analysis of surgical resections.
The study involved 50 breast cancer patients from The University of Texas MD Anderson Cancer Center, most with early stage operable disease, from whom tumor tissue, bone marrow and blood samples were obtained. DTCs and CTCs isolated from the bone marrow and blood samples with Biocept's OncoCEE™ technology, respectively, were tested for Human Epidermal growth factor Receptor-2 (HER2) by fluorescence in situ hybridization (FISH), and the results compared. Typically, 20-25% of breast cancer patients are determined to be HER2 positive, by FISH or immunohistochemistry (IHC).
"This research builds on collaborative work between MD Anderson and Biocept focused on exploring the utility of testing CTCs and DTCs in conjunction with tumor tissue from surgical biopsies of breast cancer patients for biomarkers like HER2," said Anthony Lucci, MD., Professor, Department of Surgical Oncology, Division of Surgery at MD Anderson. "We found in a number of cases discordance of HER2 status between primary tumors and CTCs or DTCs. Specifically, HER2 positive CTCs and DTCs were found in a significant number of patients with HER2 negative primary tumors. Since HER2 was analyzed by FISH, we feel the testing is rigorous. This pilot study supports the need for